01 August 2005
A randomized trial of prostaglandin E(2) gel and extra-amniotic saline infusionwith high dose oxytocin for cervical ripening.
Seyedeh-Hajar Sharami, Froozan Milani, Ziba Zahiri, Fariborz Mansour-GhanaeiMed Sci Monit 2005; 11(8): CR381-386 :: ID: 201385
Abstract
Background: Our purpose was to compare the efficacy of extra-amniotic salineinfusion plus high dose oxytocin with prostaglandin E(2) intracervical gel (Dinoprostone) for preinductioncervical ripening. Material/Methods: 166 nulliparous women with term pregnancies, vertex presentation,intact membranes and a Bishop score (2) intracervical gel and extra-amniotic saline infusion (EASI) plushigh-dose oxytocin. Changes in the Bishop scores, labor progress, various labor end points and outcomesof labor were assessed. Data were analyzed using chi(2) analysis or the Student t-test. Results: 151women were studied after 15 exclusions, 75 were assigned to PGE(2), and 76 to EASI. The groups were similarin age, race, indication for induction and gestational age. The EASI group had a significant improvementin Bishop score and greater dilation. The mean time to vaginal delivery was 11.4+/-4.8 hours and 18.9+/-6.4hours for the EASI and PGE(2) groups respectively (P=0.001). The cesarean delivery rate was not significantlydifferent between the two groups (25% for the EASI group; 34.6% for the PGE(2) group). The cesarean ratedue to failure to progress, fetal labor intolerance, and maternal and neonatal outcomes were similarin the two groups. Conclusions: Preinduction cervical ripening with EASI plus high dose oxytocin resultedin greater changes in Bishop score, and shorter time to normal vaginal delivery than with PGE(2) gelin nulliparous women, without increasing the cesarean rate due to failure to progress or fetal laborintolerance.
Keywords: Cervical Ripening - drug effects, Amniotic Fluid, Cervical Ripening - drug effects, Dinoprostone - pharmacology, Gels, Infant, Newborn, Labor, Obstetric - drug effects, Oxytocin - pharmacology, Pregnancy, Pregnancy Outcome, Sodium Chloride - pharmacology
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952